818 related articles for article (PubMed ID: 12606516)
21. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Atageldiyeva KK; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Diabetologia; 2016 Mar; 59(3):533-41. PubMed ID: 26693710
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
Farilla L; Hui H; Bertolotto C; Kang E; Bulotta A; Di Mario U; Perfetti R
Endocrinology; 2002 Nov; 143(11):4397-408. PubMed ID: 12399437
[TBL] [Abstract][Full Text] [Related]
24. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
Kluz J; Adamiec R
Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
[TBL] [Abstract][Full Text] [Related]
25. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
Tourrel C; Bailbé D; Meile MJ; Kergoat M; Portha B
Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
[TBL] [Abstract][Full Text] [Related]
26. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
McIntosh CH; Demuth HU; Kim SJ; Pospisilik JA; Pederson RA
Int J Biochem Cell Biol; 2006; 38(5-6):860-72. PubMed ID: 16442340
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
[TBL] [Abstract][Full Text] [Related]
28. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.
Ahrén B; Holst JJ; Mårtensson H; Balkan B
Eur J Pharmacol; 2000 Sep; 404(1-2):239-45. PubMed ID: 10980284
[TBL] [Abstract][Full Text] [Related]
29. Patients With Long-QT Syndrome Caused by Impaired
Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
[TBL] [Abstract][Full Text] [Related]
30. Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin.
Iida A; Seino Y; Fukami A; Maekawa R; Yabe D; Shimizu S; Kinoshita K; Takagi Y; Izumoto T; Ogata H; Ishikawa K; Ozaki N; Tsunekawa S; Hamada Y; Oiso Y; Arima H; Hayashi Y
Diabetologia; 2016 Jul; 59(7):1533-1541. PubMed ID: 27053237
[TBL] [Abstract][Full Text] [Related]
31. The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.
Lotfy M; Singh J; Rashed H; Tariq S; Zilahi E; Adeghate E
Cell Tissue Res; 2014 Nov; 358(2):343-58. PubMed ID: 25115772
[TBL] [Abstract][Full Text] [Related]
32. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
Freyse EJ; Berg S; Kohnert KD; Heinke P; Salzsieder E
Biol Chem; 2011 Mar; 392(3):209-15. PubMed ID: 21281062
[TBL] [Abstract][Full Text] [Related]
33. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract][Full Text] [Related]
34. Role of zonulin and GLP-1/DPP-IV in alleviation of diabetes mellitus by peptide/polypeptide fraction of Aloe vera in streptozotocin- induced diabetic wistar rats.
Babu SN; Govindarajan S; Vijayalakshmi MA; Noor A
J Ethnopharmacol; 2021 May; 272():113949. PubMed ID: 33610707
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst JJ; Deacon CF
Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
[TBL] [Abstract][Full Text] [Related]
36. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
37. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.
Perfetti R; Zhou J; Doyle ME; Egan JM
Endocrinology; 2000 Dec; 141(12):4600-5. PubMed ID: 11108273
[TBL] [Abstract][Full Text] [Related]
38. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
39. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
